Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:IGXT NASDAQ:KYNB NYSEAMERICAN:SER NYSEAMERICAN:TOVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AKYNBKyntra Bio$7.21+2.3%$7.06$6.32▼$12.60$28.50M0.9616,386 shs3,594 shsSERSerina Therapeutics$2.09-4.1%$1.90$1.22▼$7.92$32.69M1.1147,554 shs17,230 shsTOVXTheriva Biologics$0.23+0.4%$0.27$0.16▼$0.86$7.73M1.092.54 million shs517,005 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%KYNBKyntra Bio-2.63%-4.09%+5.07%-0.28%+703,999,900.00%SERSerina Therapeutics+2.35%+6.34%+3.81%+6.86%+217,999,900.00%TOVXTheriva Biologics-4.98%-2.14%-8.80%-32.39%-52.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AKYNBKyntra Bio$7.21+2.3%$7.06$6.32▼$12.60$28.50M0.9616,386 shs3,594 shsSERSerina Therapeutics$2.09-4.1%$1.90$1.22▼$7.92$32.69M1.1147,554 shs17,230 shsTOVXTheriva Biologics$0.23+0.4%$0.27$0.16▼$0.86$7.73M1.092.54 million shs517,005 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%KYNBKyntra Bio-2.63%-4.09%+5.07%-0.28%+703,999,900.00%SERSerina Therapeutics+2.35%+6.34%+3.81%+6.86%+217,999,900.00%TOVXTheriva Biologics-4.98%-2.14%-8.80%-32.39%-52.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXTIntelGenx Technologies 0.00N/AN/AN/AKYNBKyntra Bio 2.60Moderate Buy$32.50351.08% UpsideSERSerina Therapeutics 3.00Buy$8.00282.78% UpsideTOVXTheriva Biologics 3.00Buy$1.00334.78% UpsideCurrent Analyst Ratings BreakdownLatest TOVX, KYNB, SER, and IGXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026KYNBKyntra Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$35.007/1/2026SERSerina Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/1/2026SERSerina Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.006/16/2026KYNBKyntra Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/9/2026KYNBKyntra Bio Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39KYNBKyntra Bio$6.44M4.53N/AN/A($4.20) per share-1.72SERSerina Therapeutics$130K241.15N/AN/A($0.46) per share-4.54TOVXTheriva BiologicsN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXTIntelGenx Technologies-$9.93M-$0.06N/AN/AN/AN/AN/AN/AN/AKYNBKyntra Bio$183.45M$40.460.18N/AN/A2,199.13%N/A-36.71%N/ASERSerina Therapeutics-$19.18MN/AN/AN/AN/AN/A-8,051.54%-155.08%N/ATOVXTheriva Biologics-$23.74M-$33.06N/AN/AN/AN/A-178.29%-59.96%N/ALatest TOVX, KYNB, SER, and IGXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SERSerina TherapeuticsN/A-$0.58N/A-$0.58N/AN/A5/5/2026Q1 2026TOVXTheriva BiologicsN/A-$0.05N/A-$0.05N/A$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AKYNBKyntra BioN/AN/AN/AN/AN/ASERSerina TherapeuticsN/AN/AN/AN/AN/ATOVXTheriva BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXTIntelGenx TechnologiesN/AN/AN/AKYNBKyntra BioN/A3.613.48SERSerina Therapeutics0.244.184.18TOVXTheriva Biologics0.111.631.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXTIntelGenx TechnologiesN/AKYNBKyntra Bio72.71%SERSerina Therapeutics12.50%TOVXTheriva Biologics6.17%Insider OwnershipCompanyInsider OwnershipIGXTIntelGenx Technologies42.05%KYNBKyntra Bio4.15%SERSerina Therapeutics17.70%TOVXTheriva Biologics1.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableKYNBKyntra Bio5704.05 million3.88 millionN/ASERSerina TherapeuticsN/A15.00 million12.34 millionN/ATOVXTheriva Biologics2033.74 million33.40 millionNot OptionableTOVX, KYNB, SER, and IGXT HeadlinesRecent News About These CompaniesTheriva Biologics (NYSEAMERICAN:TOVX) Trading 2.6% Higher - Here's WhyJuly 15, 2026 | americanbankingnews.comTheriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec ...July 7, 2026 | finance.yahoo.comTheriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal AdenocarcinomaJuly 7, 2026 | globenewswire.comTheriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer ResearchJune 11, 2026 | globenewswire.comTheriva Biologics Faces Quorum Issue Delaying Warrant VoteJune 5, 2026 | tipranks.comAlliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)May 7, 2026 | theglobeandmail.comTheriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial ResultsMay 5, 2026 | globenewswire.comTheriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Trial ResultsApril 21, 2026 | blockonomi.comTheriva Biologics stock surges on AACR cancer trial dataApril 21, 2026 | investing.comTheriva Biologics Highlights Positive VCN-01 Pancreatic Cancer DataApril 20, 2026 | theglobeandmail.comTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual ...April 19, 2026 | finance.yahoo.comTherivaâ„¢ Biologics anuncia la próxima presentación de datos adicionales del ensayo clÃnico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026April 18, 2026 | globenewswire.comTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual MeetingApril 17, 2026 | globenewswire.comTheriva Biologics (TOVX) price target decreased by 37.50% to 2.55April 10, 2026 | msn.comMaxim Group upgrades Theriva Biologics (TOVX)April 1, 2026 | msn.comTheriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal AdenocarcinomaMarch 23, 2026 | markets.businessinsider.comTheriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial ResultsMarch 12, 2026 | markets.businessinsider.comTheriva Biologics licenses SYN-020 to Rasayana Therapeutics for multiple indicationsFebruary 19, 2026 | thepharmaletter.comTTheriva Biologics, Inc.: Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple IndicationsFebruary 18, 2026 | finanznachrichten.deTheriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple IndicationsFebruary 18, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Ways to Play Prime Day That Aren’t AmazonBy Thomas Hughes | June 23, 20263 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress TestBy Leo Miller | July 1, 2026Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term InvestorsBy Thomas Hughes | July 6, 20263 Waste Stocks Turning AI Investments into GrowthBy Chris Markoch | June 27, 2026The Quantum Bubble Is Real Enough to Take SeriouslyBy Nathan Reiff | June 30, 2026TOVX, KYNB, SER, and IGXT Company DescriptionsIntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 07/17/2026IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Kyntra Bio NASDAQ:KYNB$7.20 +0.17 (+2.34%) Closing price 03:59 PM EasternExtended Trading$7.20 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Serina Therapeutics NYSEAMERICAN:SER$2.09 -0.09 (-4.13%) Closing price 04:10 PM EasternExtended Trading$2.11 +0.02 (+1.00%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.Theriva Biologics NYSEAMERICAN:TOVX$0.23 +0.00 (+0.44%) Closing price 04:10 PM EasternExtended Trading$0.23 +0.00 (+0.43%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
